Supplementary Figures S1-S7 from Sotorasib Is a Pan-<i>RAS</i><sup>G12C</sup> Inhibitor Capable of Driving Clinical Response in <i>NRAS</i><sup>G12C</sup> Cancers

Supplementary Figure S1 shows IC50 values of KRASG12C inhibitors for KRASG12C, NRASG12C, HRASG12C.

Supplementary Figure S2 shows inhibition of NRASG12C by sotorasib in 293T and MOLT-4 cells.

Supplementary Figure S3 shows effect of amino acid substitutions in NRASG12C or KRASG12C on signaling in response to sotorasib and adagrasib.

Supplementary Figure S4 who's location of isoform-variable residues relative to Switch-II binders.

Supplementary Figure S5 shows crystal structures of KRASG12C inhibitors and interactions with His95.

Supplementary Figure S6 shows chemical structures of switch-II pocket-binding KRASG12C inhibitors.

Supplementary Figure S7 shows structural model of sotorasib interaction with Leu95.